Andrew Tutt

35PUBLICATIONS

283CO-AUTHORS

Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (35)

Sort by Publication Date:

|Jul 15, 2026

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|May 06, 2026

Two decades of PARP inhibitor synthetic lethality in cancer.

|Apr 28, 2026

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.

|Mar 12, 2026

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Callum Walker, Gabriel Kollarovic, Daniel Weekes

|Mar 06, 2026

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

Winnie Fernando, Jarama Clucas, Alberto Rizzo

|Oct 23, 2025

An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.

Alicia M Chenoweth, Anthony Cheung, Jitesh Chauhan

Pageof 6

Frequent Collaborators

14 joint publications

Christopher J Lord

11 joint publications

Syed Haider

10 joint publications

Anita Grigoriadis

Stephen J Pettitt

Dragomir B Krastev

Sheeba Irshad

Jyoti S Choudhary

Sophia N Karagiannis

Clare M Isacke

Andrew Wicks

Frequent Collaborators

14 joint publications

Christopher J Lord

11 joint publications

Syed Haider

10 joint publications

Anita Grigoriadis

9 joint publications

Stephen J Pettitt